uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

QURE uniQure N.V.

盘前交易 02-05 06:53:18 EST

26.65

-1.15

-4.14%

盘前26.50

-0.15-0.56%

06:52 EST

最高28.04	最低25.32	成交量224.06万
今开27.61	昨收27.80	日振幅9.77%
总市值16.60亿	流通市值10.83亿	总股本6,229万
成交额5,886万	换手率5.51%	流通股本4,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure N.V.","latestPrice":26.65,"timestamp":1770238800000,"preClose":27.8,"halted":0,"volume":2240602,"hourTrading":{"tag":"盘前","latestPrice":26.5,"preClose":26.65,"latestTime":"06:52 EST","volume":25,"amount":662.5,"timestamp":1770292374749,"change":-0.15,"changeRate":-0.005629,"amplitude":0},"delay":0,"changeRate":-0.04136690647482022,"floatShares":40636300,"shares":62291663,"eps":-4.344329,"marketStatus":"盘前交易","change":-1.15,"latestTime":"02-05 06:53:18 EST","open":27.61,"high":28.035,"low":25.32,"amount":58858584.554588,"amplitude":0.097662,"askPrice":27.49,"askSize":82,"bidPrice":26.02,"bidSize":16,"shortable":3,"etf":0,"ttmEps":-4.344329,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770301800000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":26.65,"preHourTrading":{"tag":"盘前","latestPrice":26.5,"preClose":26.65,"latestTime":"06:52 EST","volume":25,"amount":662.5,"timestamp":1770292374749,"change":-0.15,"changeRate":-0.005629,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":26.93,"preClose":26.65,"latestTime":"19:39 EST","volume":197124,"amount":5252469.1348,"timestamp":1770251968488,"change":0.28,"changeRate":0.010507,"amplitude":0.034897},"volumeRatio":1.0119603583198769,"impliedVol":1.8403,"impliedVolPercentile":0.952},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2603986676","title":"Uniqure N.V.盘中异动 下午盘大幅拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603986676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603986676?lang=zh_cn&edition=full","pubTime":"2026-01-15 02:30","pubTimestamp":1768415414,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日02时30分，Uniqure N.V.股票出现波动，股价快速上涨5.02%。截至发稿，该股报22.58美元/股，成交量82.5768万股，换手率1.33%，振幅6.74%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.17%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115023014953ccbf2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115023014953ccbf2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"1136475398","title":"异动解读 | 监管挑战致uniQure股价盘中大跌8.82%，AMT-130药物前景不明","url":"https://stock-news.laohu8.com/highlight/detail?id=1136475398","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136475398?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:03","pubTimestamp":1762787003,"startTime":"0","endTime":"0","summary":"周一盘中，生物技术公司uniQure N.V.股价大跌8.82%，主要原因是其用于治疗亨廷顿病的AMT-130药物面临监管挑战。尽管如此，uniQure管理层表示仍然相信AMT-130的潜力，并计划与FDA紧密合作推进该项目。除AMT-130外，uniQure的其他项目如AMT-260和AMT-191显示出早期临床进展，预计2026年会有更新数据。截至报告期末，uniQure拥有6.492亿美元现金储备，预计可支持运营至2029年。尽管公司整体财务状况稳健，但AMT-130的监管不确定性仍然是投资者关注的焦点，这也是导致股价大跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0},{"id":"1135225871","title":"uniQure 2025年第三季度业绩会总结及问答精华：AMT-130的监管挑战与未来展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1135225871","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135225871?lang=zh_cn&edition=full","pubTime":"2025-11-10 23:01","pubTimestamp":1762786875,"startTime":"0","endTime":"0","summary":"公司仍然相信AMT-130的潜力，并计划与FDA紧密合作以推进该项目。研发费用增加至3440万美元，反映了AMT-130的BLA准备工作。现金储备为6.492亿美元，预计可支持运营至2029年。问题1：AMT-130的外部对照组是如何构建的？患者和医生社区对AMT-130充满期待，并积极合作推动项目进展。管理层对AMT-130的潜力充满信心，但对FDA的反馈表示失望和意外。AMT-162项目因剂量限制毒性暂停，需进一步评估。uniQure在2025年第三季度面临重大监管挑战，特别是AMT-130在亨廷顿病项目上的不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"gpt_icon":0},{"id":"1175225490","title":"uniQure盘初暴跌60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175225490","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175225490?lang=zh_cn&edition=full","pubTime":"2025-11-03 22:44","pubTimestamp":1762181057,"startTime":"0","endTime":"0","summary":"周一，基因治疗公司 $uniQure N.V.(QURE)$ 暴跌60%。据报道，FDA表示该公司的一项重要症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE"],"gpt_icon":0},{"id":"1196508406","title":"uniQure N.V.在美上市股票盘前下跌66.2%，因FDA称其亨廷顿舞蹈症治疗临床数据不足","url":"https://stock-news.laohu8.com/highlight/detail?id=1196508406","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196508406?lang=zh_cn&edition=full","pubTime":"2025-11-03 20:34","pubTimestamp":1762173298,"startTime":"0","endTime":"0","summary":"uniQure N.V.在美上市的股票在盘前交易中下跌了66.2%，原因是美国食品药品监督管理局（FDA）表示该公司的亨廷顿舞蹈症治疗方案的临床数据未达标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"64989c908af4d31938f65fabf9403946","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QURE","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2576772599","title":"Uniqure N.V.盘中异动 临近收盘股价大跌5.01%报59.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2576772599","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576772599?lang=zh_cn&edition=full","pubTime":"2025-10-17 03:33","pubTimestamp":1760643232,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日03时33分，Uniqure N.V.股票出现异动，股价大幅下跌5.01%。截至发稿，该股报59.69美元/股，成交量187.013万股，换手率3.04%，振幅8.48%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.36%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025101703335297325a88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","QURE","PRAX"],"gpt_icon":0},{"id":"2574338534","title":"Uniqure N.V.盘中异动 早盘大幅下挫5.06%报60.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2574338534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574338534?lang=zh_cn&edition=full","pubTime":"2025-10-10 23:29","pubTimestamp":1760110181,"startTime":"0","endTime":"0","summary":"北京时间2025年10月10日23时29分，Uniqure N.V.股票出现异动，股价大幅下跌5.06%。截至发稿，该股报60.43美元/股，成交量142.447万股，换手率2.31%，振幅5.47%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.72%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010232941a4599d8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251010232941a4599d8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2570895044","title":"Uniqure N.V.盘中异动涨3.46% 振幅达9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570895044","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570895044?lang=zh_cn&edition=full","pubTime":"2025-09-27 02:15","pubTimestamp":1758910502,"startTime":"0","endTime":"0","summary":"北京时间2025年09月27日02时15分，Uniqure N.V.股票出现波动，股价急速拉升3.46%。截至发稿，该股报54.47美元/股，成交量809.726万股，换手率14.76%，振幅9.93%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.03%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至02时15分，《坎托·菲茨杰拉德维持uniQure NV买入评级，上调目标价至80美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092702150395476a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025092702150395476a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2570887317","title":"生物技术公司uniQure将公开发行股票筹资3亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570887317","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570887317?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:49","pubTimestamp":1758898140,"startTime":"0","endTime":"0","summary":"生物技术公司uniQure(QURE)早盘下跌2.6%，该公司将扩模后的3亿美元公开发行定价为每股47.50美元。所筹资金将支持公司持续进行临床试验和产品开发，巩固其在基因治疗市场的地位。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-09-26/doc-infrvwzm4733942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","QURE","SINA"],"gpt_icon":0},{"id":"2570033730","title":"uniQure(QURE.US)因基因疗法AMT-130大涨 高盛唱多：峰值销售额有望达25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570033730","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570033730?lang=zh_cn&edition=full","pubTime":"2025-09-26 16:37","pubTimestamp":1758875830,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，高盛最新深度分析报告聚焦uniQure NV基因疗法AMT-130在亨廷顿病治疗中的突破性进展及商业前景。近日，该股已因为该疗法消息出现大涨。商业前景方面，高盛模型预测AMT-130全球峰值销售额可达25亿美元，成功概率90%。uniQure计划初期聚焦美国约2万确诊有症状患者中的6000人进行市场推广，假设累计渗透率约25%。uniQure通过与监管机构的持续沟通及严谨的临床数据积累，正稳步推进这一创新疗法的商业化进程，为患者和投资者创造双重价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349857.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4550","LU1868836757.USD","IE0004086264.USD","IE0004091025.USD","BK4504","LU0251142724.SGD","IE00BSNM7G36.USD","LU2237443622.USD","IE00B19Z3581.USD","LU1868836914.USD","LU2237443895.HKD","LU2471134523.USD","LU1668664300.SGD","LU0048573561.USD","IE00B19Z3B42.SGD","LU0251131958.USD","QURE","BK4219","BK4554","IE00BFXG1179.USD","LU1894683264.USD","LU0742534661.SGD","LU1868837300.USD","LU1791807156.HKD","BK4516","LU1894683348.USD","LU2237443465.HKD","LU2471134796.USD","LU2750360997.AUD","BK4581","LU0061475181.USD","LU2265009873.SGD","LU2471134952.CNY","LU1804176565.USD","LU1868836591.USD","LU2750360641.GBP","BK4534","BK4084","BK4127","LU0096364046.USD","BK4533","IE0002270589.USD","LU1868837136.USD","LU2237438978.USD","BK4585","LU2237443978.SGD","LU2471134879.HKD","LU0106831901.USD","AMT"],"gpt_icon":0},{"id":"2570078576","title":"Uniqure N.V.盘中异动 早盘急速拉升7.41%报51.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570078576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570078576?lang=zh_cn&edition=full","pubTime":"2025-09-25 21:31","pubTimestamp":1758807070,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日21时31分，Uniqure N.V.股票出现波动，股价快速拉升7.41%。截至发稿，该股报51.02美元/股，成交量206.269万股，换手率3.76%，振幅2.88%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.02%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至21时31分，《坎托·菲茨杰拉德维持uniQure NV买入评级，维持目标价47美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925213111a69dccf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925213111a69dccf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"1107670505","title":"生物技术公司UniQure股价为何一日暴涨两倍，并带动ClearPoint股价一同飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=1107670505","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107670505?lang=zh_cn&edition=full","pubTime":"2025-09-25 07:39","pubTimestamp":1758757153,"startTime":"0","endTime":"0","summary":"UniQure还与Hercules Capital签订了一项1.75亿美元的定期贷款协议以支持可能的疗法上市。ClearPoint Neuro通过其称为SmartFlow Cannula的医疗设备为大脑和脊柱的基因疗法提供导航，UniQure使用的正是该技术。Schock表示，UniQure预计最初将在美国瞄准约6,000名可治疗患者。Schock表示，如果获得批准，B. Riley Securities预计UniQure的AMT-130将推动诊断率的提高，可能使确诊人数翻倍。今年以来，ClearPoint Neuro股价上涨了25%，而UniQure的股价上涨了169%。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/c2ddfdc2480af7e7bfd27e5cd2b9d3c2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/c2ddfdc2480af7e7bfd27e5cd2b9d3c2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"生物技术公司UniQure股价为何一日暴涨两倍，并带动ClearPoint股价一同飙升","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","CLPT"],"gpt_icon":0},{"id":"2569764700","title":"美股异动 | 亨廷顿病关键研究取得积极进展 uniQure(QURE.US)暴涨超186%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569764700","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569764700?lang=zh_cn&edition=full","pubTime":"2025-09-24 22:29","pubTimestamp":1758724195,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，uniQure(QURE.US)暴涨超186%，创四年新高，报39.11美元。消息面上，9月24日，该公司宣布与Hercules Capital达成1.75亿美元非稀释性高级担保定期贷款协议，包括现有5000万美元债务再融资，额外1.25亿美元融资可提取，利息率降至9.70%，显著改善财务灵活性。此外，该公司公布AMT-130在亨廷顿病1/2期关键研究中达到主要终点，高剂量组36个月数据显示疾病进展减缓75%cUHDRS测量，同时关键次要终点TFC测量显示疾病进展减缓60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 亨廷顿病关键研究取得积极进展 uniQure(QURE.US)暴涨超186%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2569767126","title":"Uniqure N.V.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2569767126","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569767126?lang=zh_cn&edition=full","pubTime":"2025-09-22 23:07","pubTimestamp":1758553653,"startTime":"0","endTime":"0","summary":"北京时间2025年09月22日23时07分，Uniqure N.V.股票出现异动，股价急速上涨5.08%。截至发稿，该股报14.58美元/股，成交量51.9787万股，换手率0.95%，振幅5.78%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.75%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922230734a43cb323&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250922230734a43cb323&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2568528645","title":"Uniqure N.V.盘中异动 股价大涨5.01%报14.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568528645","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568528645?lang=zh_cn&edition=full","pubTime":"2025-09-19 03:08","pubTimestamp":1758222500,"startTime":"0","endTime":"0","summary":"北京时间2025年09月19日03时08分，Uniqure N.V.股票出现异动，股价快速上涨5.01%。截至发稿，该股报14.87美元/股，成交量75.5971万股，换手率1.38%，振幅4.91%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.17%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。消息层面，截至03时08分，《瑞穗证券维持uniQure NV买入评级，维持目标价30美元》资讯为影响Uniqure N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919030821a728cb66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250919030821a728cb66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2558662355","title":"Uniqure N.V.盘中异动 下午盘股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558662355","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558662355?lang=zh_cn&edition=full","pubTime":"2025-08-12 01:33","pubTimestamp":1754933600,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日01时33分，Uniqure N.V.股票出现异动，股价大幅拉升5.05%。截至发稿，该股报13.95美元/股，成交量44.494万股，换手率0.81%，振幅7.61%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.27%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201332194dd1794&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081201332194dd1794&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"2518086206","title":"Uniqure N.V.盘中异动 快速下挫5.07%报11.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518086206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518086206?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:08","pubTimestamp":1741630111,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时08分，Uniqure N.V.股票出现异动，股价快速下挫5.07%。截至发稿，该股报11.61美元/股，成交量35.4258万股，换手率0.66%，振幅4.29%。Uniqure N.V.股票所在的生物技术行业中，整体涨幅为0.70%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102083198a2d36f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031102083198a2d36f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE","BK4139"],"gpt_icon":0},{"id":"2517145843","title":"Uniqure N.V.2024财年实现净利润-2.40亿美元，同比增加22.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517145843","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517145843?lang=zh_cn&edition=full","pubTime":"2025-03-08 00:00","pubTimestamp":1741363239,"startTime":"0","endTime":"0","summary":"3月8日，Uniqure N.V.公布财报，公告显示公司2024财年净利润为-2.40亿美元，同比增加22.08%；其中营业收入为27.12百万美元，同比增加71.21%，每股基本收益为-4.92美元。从资产负债表来看，Uniqure N.V.总负债5.63亿美元，其中短期债务3.60百万美元，资产负债比为0.99，流动比率为0.10。机构评级：截至2025年3月8日，当前有10家机构对Uniqure N.V.目标价做出预测，其中目标均价为36.20美元，其中最低目标价为18.00美元，最高目标价为70.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000100a2647e79&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000100a2647e79&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["QURE"],"gpt_icon":0},{"id":"2517195096","title":"Uniqure N.V.盘中异动 股价大涨5.05%报12.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517195096?lang=zh_cn&edition=full","pubTime":"2025-03-07 02:01","pubTimestamp":1741284074,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日02时01分，Uniqure N.V.股票出现波动，股价大幅拉升5.05%。截至发稿，该股报12.70美元/股，成交量40.313万股，换手率0.75%，振幅9.93%。Uniqure N.V.股票所在的生物技术行业中，整体跌幅为0.83%。Uniqure N.V.公司简介：uniQure NV 是一家基因治疗公司。该公司专注于与 Bristol Myers Squibb 合作开发用于心血管疾病的基因疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307020115abebaa25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307020115abebaa25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","QURE"],"gpt_icon":0},{"id":"1170718364","title":"异动解读 | uniQure 公司股价盘中大涨5.08%,主要受公司业绩良好前景看好因素提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1170718364","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170718364?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:50","pubTimestamp":1741204219,"startTime":"0","endTime":"0","summary":"uniQure N.V.作为一家基因治疗公司,专注于开发用于治疗血友病、亨廷顿病等遗传性疾病的疗法,同时也与Bristol Myers Squibb合作开发心血管疾病的基因疗法。\n\n近期该公司公布的财报显示,尽管净利润为负,但营收同比有所增长,市场对公司长期发展前景保持看好。uniQure获得了12家机构的看好评级,有83%机构给予该股\"买入\"评级,也反映了机构对公司未来发展的乐观预期。\n\n因此,基于公司在基因治疗领域的前景获得认可,以及机构看好评级的影响,该公司股价在盘中出现了5.08%的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | uniQure 公司股价盘中大涨5.08%,主要受公司业绩良好前景看好因素提振","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["QURE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":0.1577},{"period":"1month","weight":0.1776},{"period":"3month","weight":-0.0313},{"period":"6month","weight":1.0068},{"period":"1year","weight":0.675},{"period":"ytd","weight":0.1137}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0022},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.0769},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.0063}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"uniQure N.V.作为私人有限责任公司于2012年1月9日依照荷兰相关法律条文成立。公司是一家专业从事基因治疗的生物技术企业，致力于为罕见病和重病患者开发单一治疗途径。其管线包括针对亨廷顿病、与SOD1突变相关的肌萎缩性侧索硬化症、难治性中位颞叶癫痫和法布里病的临床候选药物，反映了对推进基因治疗领域创新疗法的关注。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.583333,"avgChangeRate":0.073295},{"month":3,"riseRate":0.25,"avgChangeRate":-0.054124},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure N.V.","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"uniQure N.V.,QURE,uniQure N.V.股票,uniQure N.V.股票老虎,uniQure N.V.股票老虎国际,uniQure N.V.行情,uniQure N.V.股票行情,uniQure N.V.股价,uniQure N.V.股市,uniQure N.V.股票价格,uniQure N.V.股票交易,uniQure N.V.股票购买,uniQure N.V.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure N.V.(QURE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供uniQure N.V.(QURE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}